Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EV302
- Development stage
- Preclinical
- Lead developer
- Astellas Pharma
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
EV302 is a preclinical-stage therapeutic candidate being developed by EV Therapeutics for the treatment of gastric cancer. The drug is part of a pipeline focused on gastrointestinal (GI) malignancies and utilizes the company's proprietary extracellular vesicle (EV) platform. This platform leverages exosomes as delivery vehicles for therapeutic payloads, aiming to enhance targeting and reduce systemic toxicity compared to traditional delivery methods. As of early 2024, specific molecular targets and the nature of the therapeutic payload for EV302 remain undisclosed by the developer.
Beyond the preview
Go deeper on EV302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EV302.